Table 2. Treatment outcomes .

P < 0.05 indicates statistical difference.

Abbreviations: BNI, Barrow Neurological Institute; RGZ, retrogasserian zone; DREZ, dorsal root entry zone.

Variable	RGZ	DREZ	P-value
n (%)	32 (65.3%)	17 (34.7%)
Follow-up (months)	36.0 (6-72)	51.0 (6-72)	0.217
Median prescription dose	90 Gy (80-94)	90 Gy (80-96)
Dose (Gy) and distance
1 mm	11.6 (2.2-35.4)	29.5 (17.5-60.1)	0.0001
2 mm	18.4 (3.2-54.0)	43.9 (27.9-69.5)	0.0001
3 mm	29.2 (4.9-78.3)	60.2 (35.8-86.7)	0.0001
4 mm	41.5 (8.2-83.5)	69.5 (47.3-90.0)	0.0001
BNI
Treatment success, n (%)	26 (81.3%)	12 (70.6%)	0.02
I	7 (21.9%)	8 (47.1%)
II	3 (9.4%)	0 (0%)
IIIa	6 (18.8%)	2 (11.8%)
IIIb	10 (31.3%)	2 (11.8%)
Treatment failure, n (%)	6 (18.8%)	5 (29.4%)
IV	4 (12.5%)	4 (23.5%)
V	2 (6.3%)	1 (5.9%)
Pain Frequency Treatment success, n (%)	22 (68.8%)	11 (64.7%)	0.055
No pain	11 (34.4%)	8 (47.1%)
Several months without pain	8 (25.0%)	2 (11.8%)
Several times per month	3 (9.4%)	1 (5.9%)
Treatment failure	10 (31.3%)	6 (35.3%)
Several times per week	8 (25.0%)	6 (35.3%)
Every day	2 (6.3%)	0 (0%)
Response time at 24 hours, n (%)	7 (21.9%)	1 (5.9%)	0.033
Mean response time in days (range)	22.3 (1-90)	34.1 (1-120)	0.277
BNI facial numbness score, n (%)
I	22 (68.9%)	11 (64.7%)	0.773
II	7 (21.9%)	6 (35.3%)
III	3 (9.4%)	0 (0%)
IV	0 (0%)	0 (0%)
Recurrence, n (%)	7 (21.9%)	5 (29.4%)	0.563
Median time of recurrence in days (range)	120 (60-900)	60 (20-710)	0.415
Quality of life, n (%)
Much better	25 (78.1%)	14 (84.2%)	0.726
No change	7 (21.8%)	3 (17.7%)